

# Daniel Soffer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9727831/publications.pdf>

Version: 2024-02-01

10  
papers

252  
citations

1307594

7  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

477  
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 139, 1661-1670.	1.6	106
2	Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease. <i>Circulation</i> , 2018, 137, 2450-2462.	1.6	46
3	Effects of Methylalntrexone on Ticagrelor-Induced Antiplatelet Effects inâ€“Coronary Artery Disease Patients Treated With Morphine. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1538-1549.	2.9	26
4	Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 083-093.	3.4	21
5	Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes. <i>JACC Basic To Translational Science</i> , 2020, 5, 419-428.	4.1	18
6	Pharmacodynamic Effects of Vorapaxarâ€“in Patientsâ€“With and Withoutâ€“Diabetes Mellitus. <i>JACC Basic To Translational Science</i> , 2019, 4, 763-775.	4.1	12
7	Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 1500-1502.	1.6	10
8	Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 728-737.	3.0	6
9	Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1341-1351.	3.4	5
10	Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 452-461.	3.0	2